Body-like models present new possibilities for testing medical products.
But the road to market maturity is paved with long-term clinical studies into the efficacy and side effects of new medicines. Having products fail during testing is disheartening, destroying hopes of a cure and using up research funds.
Which is why a London-based startup has developed a platform to examine failed drugs more closely. First an AI model analyses toxicity and potential health risks.
Possible adaptations on a molecular level are then calculated using biological and chemical data from studies and tests. Allowing the most promising drugs to be selected from the archive and given a makeover.
Others are using AI to examine lung function or evaluate endoscopy images.
